A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY TO EVALUATE THE TOLERABILITY AND EFFECTIVENESS OF ETORICOXIB 90 MG PER DAY, VS. SODIC DICLOFENACO 50 MG THREE TIMES A DAY IN PATIENTS WITH OSTEOARTHRITIS.
Not Applicable
- Conditions
- -M15M15
- Registration Number
- PER-054-02
- Lead Sponsor
- MERCK SHARP & DOHME PERU S.R.L.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients who had a clinical diagnosis of osteoarthritis and who were to require, as expected, a chronic therapy with NSAIDs or a selective COX-2 inhibitor for at least 1 year were considered eligible to enter the study after signing. an informed consent.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:Global Assessment of the Patients Disease Condition<br>Measure:The Global Assessment of the Patients Disease Condition will be collected at each study visit for each patient.<br><br>Timepoints:month 1, 4, 8 y 12<br>
- Secondary Outcome Measures
Name Time Method <br>Outcome name:Adverse experiences reported spontaneously (including related gastrointestinal experiences), physical exams, vital signs (blood pressure and heart rate), laboratory safety measurements (complete blood count (CSC), serum chemistry and urinalysis) and ECGs.<br>Measure:drug safety<br>Timepoints:month 1, 4, 8 y 12<br>